Latham & Watkins Advises on Structure Therapeutics’ Upsized US$476 Million Public Offering

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced the pricing of its upsized underwritten public offering of 9,066,972 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of US$52.50 per ADS. The aggregate gross proceeds to Structure Therapeutics from the offering are expected to be approximately US$476.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Structure Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,360,045 ADSs at the public offering price, less underwriting discounts and commissions. The offering is expected to close on June 7, 2024, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP is advising the underwriters in the offering, with a capital markets team led by San Diego partners Matt Bush and Cheston Larson, with associates Julian Brody, Omeed Valipour, and Samantha Wang.